Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study of the Safety, Tolerability and Efficacy of BRY812 for Injection in Patients With Advanced Malignancies

NCT06038058 is registered in ClinicalTrials.gov with BioRay Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06038058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06038058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study of the Safety, Tolerability and Efficacy of BRY812 for Injection in Patients With Advanced Malignancies
Lead sponsor
BioRay Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
October 10, 2023
Completion date
December 31, 2028
Enrollment
164 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies